LZLian-San Zhao

Lian-San Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lian-San Zhao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Jin Yang

    Department of Infectious Diseases, the Affiliated Shenzhen Nanshan Hospital of Guangdong Medical College, No 89, Taoyuan Road, Nanshan district, 518052 Shenzhen, China

    2 shared publications
  • ShuHua Guo

    Chengdu Sixth People's Hospital, China

    1 shared publication
  • Taixiang Wu

    West China Hospital, Sichuan University; Chinese Clinical Trial Registry, Chinese Ethics Committee of Registering Clinical Trials; No. 37, Guo Xue Xiang Chengdu Sichuan China 610041

    1 shared publication
  • Tao-You Zhou

    Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China

    1 shared publication
  • Xue-Mei Zeng

    Center of Infectious Diseases, National Key Laboratory of Biotherapy for Human Diseases, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, PR China

    1 shared publication
  • Ya-Lin Men

    Center of Infectious Diseases, National Key Laboratory of Biotherapy for Human Diseases, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, PR China

    1 shared publication

Latest Publications

  • Open Access

    Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial

    by YongLi Zheng, LianSan Zhao, TaiXiang Wu, ShuHua Guo, YaGang Chen, TaoYou Zhou

    Background: Consensus interferon (CIFN) is a newly developed type I interferon. Aims: This multicentre, controlled trial was conducted to determine the efficacy of CIFN and to compare it with alpha-1b-interferon (IFN-α1b) in the treatment of patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Methods: 144 Patients were randomly assigned to receive 9 μg CIFN (CIFN group) or 50 μg INF-α1b (IFN-alpha group) subcutaneously 3 times weekly for 24 weeks, followed by 24 weeks of observation. Efficacy was assessed by normalization of serum alanine transaminase (ALT) levels and the non-detectability of serum hepatitis B virus DNA or HBeAg at the end of treatment and 24 weeks after stopping treatment. Results: There was no statistically significant difference in the serological, virological and biochemical parameters between CIFN and IFN-α1b groups at the end of the therapy and follow-up period (p > 0.05). Overall, at the end of treatment, 7.0% (5/71) and 35.2% (25/71) of patients in the CIFN group showed a complete or partial response compared with 7.4% (5/68) and 33.8% (23/68) of the IFN-alpha group (p = 0.10). At 24 weeks after stopping treatment, 6.9% (5/72) and 37.5% (27/72) of patients in the CIFN group showed complete response or partial response compared with 7.1% (5/70) and 34.3% (24/70) of the IFN-alpha group (p = 0.10). Conclusion: These findings suggest that 9 μg CIFN is effective in the treatment of patients with HBeAg-positive chronic hepatitis B. It can gradually induce ALT normalization and HBV DNA clearance and HBeAg loss or HBeAg/HBeAb seroconversion.


  • Open Access

    Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus – a systematic review

    by Jin Yang, Xue-Mei Zeng, Ya-Lin Men, Lian-San Zhao

    Background: Caesarean section before labor or before ruptured membranes ("elective caesarean section", or ECS) has been introduced as an intervention for preventing mother-to-child transmission (MTCT) of hepatitis B virus (HBV). Currently, no evidence that ECS versus vaginal delivery reduces the rate of MTCT of HBV has been generally provided. The aim of this review is to assess, from randomized control trails (RCTs), the efficacy and safety of ECS versus vaginal delivery in preventing mother-to-child HBV transmission. Results: We searched Cochrane Pregnancy and Childbirth Group's Trials Register (January, 2008), the Cochrane Central Register of Controlled Trials (the Cochrane Library 2008, issue 1), PubMed (1950 to 2008), EMBASE (1974 to 2008), Chinese Biomedical Literature Database (CBM) (1975 to 2008), China National Knowledge Infrastructure (CNKI) (1979 to 2008), VIP database (1989 to 2008), as well as reference lists of relevant studies. Finally, four randomized trails involving 789 people were included. Based on meta-analysis, There was strong evidence that ECS versus vaginal delivery could effectively reduce the rate of MTCT of HBV (ECS: 10.5%; vaginal delivery: 28.0%). The difference between the two groups (ECS versus vaginal delivery) had statistical significance (RR 0.41, 95% CI 0.28 to 0.60, P < 0.000001). No data regarding maternal morbidity or infant morbidity according to mode of delivery were available. Conclusion: ECS appears to be effective in preventing MTCT of HBV and no postpartum morbidity (PPM) was reported. However, the conclusions of this review must be considered with great caution due to high risk of bias in each included study (graded C).


    • 1 May 2006
      • Vol. 14  (5) , 378-9

    [Problems and strategies during interferon therapy for hepatitis B].

    by Lian-San Zhao